Hemophilia Clinical Trial Pipeline Shows Potential with Active Contributions from 80+ Key Companies | DelveInsight

DelveInsight's, "Hemophilia Pipeline Insight, 2026" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight's comprehensive Hemophilia Pipeline Report to explore emerging therapies @ https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight [https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Hemophilia Pipeline Report

* On February 11, 2026- Novo Nordisk A/S announced a study is looking at how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used to avoid bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). The study will last for up to 5.5 years. The duration of the study depends on when the participant enrolled in this study.
* On February 05, 2026- Pfizer initiated a study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005 and from the Phase 3 Study B7841008.
* On February 05, 2026- CSL Behring conducted a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B.
* On February 05, 2026- Hoffmann-La Roche announced a phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
* DelveInsight's Hemophilia pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hemophilia treatment.
* The leading Hemophilia Companies such as Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
* Promising Hemophilia Pipeline Therapies such as NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others.

Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Hemophilia Clinical Trials and Studies [https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Hemophilia Emerging Drugs Profile

* SerpinPC: Centessa Pharmaceuticals

SerpinPC, a specific inhibitor of activated protein C (APC), for the treatment of hemophilia A and hemophilia B. SerpinPC has been observed to be well-tolerated in the clinical setting, associated with promising reductions in bleeding rates, and has PK suitable for infrequent subcutaneous dosing without the need for factor replacement. SerpinPC has human genetic target validation and established proof of concept Phase 2a clinical data.

* Fitusiran: Alnylam Pharmaceuticals

Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBDs) by their collaborators at Sanofi Genzyme. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hemophilia.

* ASC 618: ASC Therapeutics

ASC618 is an AAV8-based gene therapy for the treatment of hemophilia A, affecting approximately 1 of every 5000 live-born males. ASC618 incorporates a novel liver-specific promoter and a bioengineered, codon-optimized B domain-deleted FVIII variant; in preclinical studies, ASC618 exhibits at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered gene constructs. ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells. ASC Therapeutics will conduct a phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of ASC618. The program received IND clearance from the U.S. Food and Drug Administration.

The Hemophilia Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia Treatment.
* Hemophilia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hemophilia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia market.

Get a detailed analysis of the latest innovations in the Hemophilia Pipeline. Explore DelveInsight's expert-driven report today! @ Hemophilia Unmet Needs [https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Hemophilia Companies

Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.

Hemophilia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Hemophilia Developments @ Hemophilia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Hemophilia Pipeline Report

* Coverage- Global
* Hemophilia Companies- Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
* Hemophilia Pipeline Therapies- NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others.
* Hemophilia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hemophilia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Hemophilia drug development? Find out in DelveInsight's exclusive Pipeline Report-access it now! @ Hemophilia Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Hemophilia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hemophilia- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Fitusiran: Alnylam Pharmaceuticals
* Mid Stage Products (Phase II)
* SerpinPC: Centessa Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company Name
* Preclinical and Discovery Stage Products
* Drug name: Company Name
* Inactive Products
* Hemophilia Key Companies
* Hemophilia Key Products
* Hemophilia- Unmet Needs
* Hemophilia- Market Drivers and Barriers
* Hemophilia- Future Perspectives and Conclusion
* Hemophilia Analyst Views
* Hemophilia Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hemophilia-clinical-trial-pipeline-shows-potential-with-active-contributions-from-80-key-companies-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hemophilia-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.